We want to put the power to stop seizures in the palm of your hand

Nearly 200,000 people with epilepsy in the U.S. experience seizures that cannot be prevented or stopped once they’ve started. But hope is on the horizon. In a proof of concept clinical study, Staccato Alprazolam stopped 80% of all participants’ seizures within 2 minutes.

A promising rescue therapy with the potential for fast-track FDA approval

The next step in bringing this promising seizure-stopping treatment to market is a clinical study where it can be tested with participants who are having a naturally occurring focal or generalized seizure – and this is where we need your help.

Make money and help make life with epilepsy a lot easier

We are compensating study participants for up to 8 days. During the study you will be carefully monitored while at in-patient facility. Once a seizure occurs, you can return home.

You are a good candidate for this clinical trial if you are…

  • Age 18 years or older
  • Have been diagnosed with focal or generalized epilepsy
  • Have a documented history of seizure episodes that include at least one of the following:
    • Generalized seizure episodes that start with a flurry of absence seizures or myoclonic seizures that last at least 5 minutes
    • Focal seizure episodes that last at least 3 minutes
    • Experience having 2 or more focal seizures that are separated by 2 hours or less
  • Do NOT have a history or diagnosis of other non-epileptic seizures
  • Do NOT use medication that treats an airway disease such as asthma or COPD

Clinical trial duration and process:

  • The study requires 8 to 12 weeks of involvement for each participant, including the screening and follow-up periods
  • After an initial screening, your seizure activity will be followed for 4 weeks to confirm eligibility
  • Once confirmed, you will be admitted to an inpatient facility in anticipation of a seizure at which point you will receive Alprazolam via the Staccato device or a placebo
  • You will be followed for at least 12 hours after receiving the dosage
  • After you are discharged from the inpatient facility, a study coordinator will follow up with you via phone about two weeks later to conduct a short survey